Literature DB >> 6631725

Correlation between the in vivo metabolism of hexobarbital and antipyrine in rats.

M van der Graaff, N P Vermeulen, R P Joeres, T Vlietstra, D D Breimer.   

Abstract

Two model substrates for oxidative hepatic enzyme activity, viz. hexobarbital (HB) and antipyrine (AP), were given simultaneously to rats by the oral route of administration. Blood concentrations of HB and AP were measured simultaneously by a gas chromatographic method and the urinary excretion of six metabolites arising from AP and HB also was determined; norantipyrine, 4-hydroxyantipyrine and 3-hydroxymethylantipyrine (HMA) by high-performance liquid chromatography; 3'-hydroxyhexobarbital, 3'-ketohexobarbital and 1,5-dimethylbarbituric acid by gas-liquid chromatography. The apparent intrinsic clearances of HB (CL*int,HB) and AP (CL*int,AP) and the clearance for production of the various metabolites were correlated in an attempt to establish whether HB and AP have metabolic pathways mediated by the same or very similar forms of cytochrome P-450. In order to create broadly ranging and evenly distributed clearance values, 3-methylcholanthrene (3-MC)- and phenobarbital (PB) pretreated rats were employed in conjunction with a control group of untreated animals. CL*int,HB and CL*int,AP were both increased by PB pretreatment, but 3-MC-pretreatment increased CL*int,AP, whereas CL*int,HB was decreased. CL*int,HB and CL*int,AP were found to correlate poorly, when all groups were taken into consideration (r = -0.08). The formation of AP-metabolites was inducible by both PB and 3-MC, and good correlations between rates of formation of AP-metabolites and CL*int,HB and CL3'-hydroxy-HB + 3'-keto-HB were obtained.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6631725

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  7 in total

1.  Relationship between the metabolism of antipyrine, hexobarbitone and theophylline in man as assessed by a 'cocktail' approach.

Authors:  J H Schellens; J H van der Wart; M Danhof; E A van der Velde; D D Breimer
Journal:  Br J Clin Pharmacol       Date:  1988-10       Impact factor: 4.335

2.  Research in the Division of Pharmacology.

Authors:  D D Breimer
Journal:  Pharm Weekbl Sci       Date:  1985-04-26

3.  Influence of rifampicin treatment on antipyrine clearance and metabolite formation in patients with tuberculosis.

Authors:  M W Teunissen; W Bakker; J E Meerburg-Van der Torren; D D Breimer
Journal:  Br J Clin Pharmacol       Date:  1984-11       Impact factor: 4.335

4.  Disposition of allylic oxidation pathway metabolites of racemic hexobarbital in the rat.

Authors:  M Van der Graaff; N P Vermeulen; M H Vinks; D D Breimer
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1986 Apr-Jun       Impact factor: 2.441

5.  Intra-arterial administration of hexobarbital enantiomers to the rat: disposition and estimation of apparent extraction ratio.

Authors:  M Van der Graaff; N P Vermeulen; D D Breimer
Journal:  Pharm Weekbl Sci       Date:  1986-04-25

6.  The effect of induction with phenobarbital on the kinetics and bioavailability of antipyrine in the dog.

Authors:  F P Abramson
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1988 Apr-Jun       Impact factor: 2.441

7.  Correlation between in vivo antipyrine metabolite formation and theophylline metabolism in rats.

Authors:  M W Teunissen; I O Brorens; H J De Langen; A M Geerlings; D D Breimer
Journal:  Pharm Res       Date:  1986-06       Impact factor: 4.200

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.